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Abstract 
Antipsychotics (APs) are widely used medications, however these are not 
without side effects such as disruption of blood brain barrier function 
(BBB). To investigate this further we have studied the chronic effects of 
the typical APs, chlorpromazine (CPZ) and haloperidol (HAL) and the 
atypical APs, risperidone (RIS) and clozapine (CLZ), on the bioenergetics 
of human micro-vascular endothelial cells (HBVECs) of the BBB. Alamar 
blue (AB) and ATP assays showed that these APs impair bioenergenesis in 
HBVECs in a concentration and time dependent manner. However since 
these effects were incomplete they suggest a population of cell 
bioenergetically heterogeneous, an idea supported by the bistable nature 
by which APs affected the mitochondrial transmembrane potential. CPZ, 
HAL and CLZ inhibited the activity of mitochondrial complexes I and III. 
Our data demonstrates that at therapeutic concentrations, APs can impair 
the bioenergetic status of HBVECs, an action that help explains the 
adverse side effects of these drugs when used clinically. 
Keywords: Antipsychotics; mitochondria; Blood brain barrier; endothelia; 
heterogeneity; toxicology  
Introduction 
The BBB is a specialized system of capillary endothelial cells that protects 
the central nervous system (CNS) from harmful and pathogenic blood 
constituents such as toxic solutes and bacteria.  Moreover the BBB is 
paramount to the homeostatic maintenance of CNS where it regulates the 
supply of ions, nutrients and metabolic substrates, as well as the removal 
of metabolic waste products [1]. In humans the BBB is formed by the 
brain vascular endothelium where endothelial cells are joined by multiple 
bands of zona adherens and tight junctions (zona occludens) [2]. The 
tight junctions effectively close off transepithelial transport via the 
paracellular pathway. As a result, the majority of solutes cross the BBB of 
the endothelial cell by facilitated diffusion and primary/secondary active 
transport. Primary active transport is driven by the work done by their 
inherent enyzmic ATPase activity. In addition to the cationic ATPases, 
members of the ABC transporter family such as P-glycoprotein (P-GP) and 
Multidrug resistance related protein (MRP) also have ATPase activity and 
act to regulate the flow of lipophilic substances across the BBB [1]. 
Secondary active transport processes convert the potential energy of 
trans-plasma membrane solute gradients into the movement of sugars, 
amino acids as well as various cations and anions up their electrochemical 
gradients.  Consequently, the transport role of the BBB is highly energy 
dependent; as evidenced by the greater number and volume of 
mitochondria compared to that of endothelia in peripheral vasculature [3]. 
Subsequently, the bioenergetic fitness of mitochondria of endothelial cells 
of the BBB is paramount to a healthy CNS. Many drugs that are toxic to 
mitochondria are highly lipophilic. Their ability to cross the BBB from the 
blood plasma to the CSF is prevented by the BBB [1] and compromised by 
the counter-transport activities of PGP and MRP, consequently a tipping 
point is envisaged where if a drug reaches a sufficiently high enough 
intracellular concentration to impair the mitochondrial function of BBB 
endothelial cells then a  combined action of a decrease in intracellular ATP 
and ATPase-dependent pump activities will culminate in a catastrophic 
failure of the endothelial cell to act as an effective barrier for that drug; a 
process manifest as a drug permeable conduit from the plasma into the 
CNS with associated neuropathologies [4].  Indeed, we have recently 
shown that a variety of APs can impair BBB functions at concentrations 
seen at the higher end of their therapeutic windows and with over-dosage 
[4]. The fact that this effect was associated with decreased cellular redox 
potential and increased ROS production, implicates that the adverse 
action of APs on endothelial cells of the BBB was most likely mediated by 
mitochondrial dysfunction. We have now investigated this possibility by 
studying the direct chronic effects of antipsychotics on mitochondrial 
function in cultured endothelial cells derived from the vasculature of the 
human BBB (HBVECs). 
Materials and methods 
Chemicals and reagents 
The selection of neuroleptic drugs was based upon those routinely 
prescribed for patients being treated for schizophrenia or bipolar disorder: 
chlorpromazine (CPZ), haloperidol (HAL), risperidone (RIS) and clozapine 
(CLZ) (Abcam). Stock solutions of drugs were all made in ethanol 
(vehicle). Drugs were tested with the cells in culture. Mitochondria were 
isolated with the Qproteome Mitochondria Isolation Kit (Cat. no. 37612). 
Unless stated all other chemicals were purchased from Sigma-Aldrich. 
Cells 
HBVECs were  grown and maintained in RPMI-1640 medium which also 
contained heat inactivated 20% Foetal Bovine Serum, 2mM L-glutamine, 
1mM sodium pyruvate, 1% minimum essential media (MEM) vitamins, 1% 
MEM non-essential amino acids, 100 units of penicillin-G ml-1, and 100 µg 
of streptomycin sulphate ml-1 as previously described [4]. When 
confluent, our HBVECs demonstrated morphological and transport 
properties consistent with a functional endothelium identity [4].  
Alamar blue and ATP assay: 
The Alamar blue (AB) assay was used to measure redox state 
(Invitrogen). Cells were seeded at 104 per well in 96 well plates (Nunc), 
pre-incubated for 24hr in RPMI followed by a further incubation for 4hr, 
24hr, 48hr or 72hr in the presence of vehicle or test drug. The ATP assay 
(Abcam) followed the same incubation steps as above, but with the 
experiment terminated by the addition of cell lysis buffer. Data is 
expressed as a percentage of control. Each experiment was performed in 
triplicate, with the mean result counting as a single experimental value. 
 
Mitochondrial Membrane Potential. 
The cationic dye: DePsipher (Trevigen) was used with flow cytometry to 
monitor the distribution of mitochondrial membrane potential (ΔΨm) in 
cells pre-incubated for 24 hr in RPMI in the presence of vehicle or test 
drug. Data was analysed with Weasel software, V2.7.4.  
 
Cell respiration. 
The O2 consumption rate (OCR) of endothelial cell suspensions of known 
cell density was measured polarographically using Clark oxygen 
electrodes (Rank Brothers) following the protocol of Daunt et al [5]. 
Experiments were performed at 37°C in a solution that contained (in mM): 
5.6 KCl, 138 NaCl, 4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 1.2 MgCl2, 10 
HEPES (pH 7.4 with NaOH), and 0.1% (wt/vol) BSA. Prior to the 
measurement of OCR, cells were pre-incubated for 24 hrs in RPMI in the 
presence of vehicle or test drug. Background, non-respiratory, oxygen 
consumption was determined by the addition of 6 mM NaN3 to block 
oxidative respiration at cytochrome aa3. OCR was measured for each 
condition as the rate of change in [O2]aq over a 5-minute time period.  
 
Mitochondrial complex assay 
Confluent HBVECs were pre-incubated for 24 hrs with either vehicle or 
vehicle or test drug. For the complex assays, a mitochondrial enriched 
fraction and cell lysate was prepared as described by [6]. Complex I was 
assayed following the protocol of [7]. Specific Complex I activity was 
calculated as the difference between that measured in the absence and 
presence of 2 µM rotenone. Complex III activity was measured by the 
ability of the cell lysate to reduce cytochrome c monitored by the change 
in absorbance at 550 nm. Background was corrected by subtraction of the 
absorbance of samples without lysate. Specific complex III activity was 
calculated as the difference between that measured in the absence and 
presence of 2 µM antimycin A. The activities of the complexes were 
normalised to that measured in vehicle control with the assumption that 
these possessed 100% activity. 
 
Statistical analysis: 
Concentration-response relationships were constructed from single dose 
concentration experiments. The concentration-response relationships 
were quantified by fitting the data with the following equation: 
Y      =            100        .     
              (1 + ([D]/IC50))  
Where Y is the magnitude of drug effect as a percentage of the control, 
[D] is the concentration of drug; IC50 is the concentration of drug that 
produces a half-maximal effect. IC50 values are quoted with 95% 
confidence intervals. Data were tested for Normal distribution with the 
D'Agostino & Pearson omnibus normality test and were compared using 
the appropriate statistical test as indicated in the text. These procedures 
were all performed using PRISM 6 (GraphPad Software Inc., San Diego, 
CA).  The fitting of equations to data used a least squares algorithm as 
supplied with PRISM. Statistical significance is defined as P <0.05 and is 
flagged as * in graphics, ** when P <0.01, *** when P <0.001 or **** 
when P <0.0001. 
 Results 
Alamar blue and intracellular ATP assays 
All four APs decreased the ability of HBVECs to reduce AB, an action that 
increased with time and concentration (Fig. 1), however, the block was 
never complete. For HAL and CLZ the maximal block was independent of 
incubation time, whereas it increased with incubation time for RIS (r =-
0.98, p<0.01, Pearson) and CLZ (r =-0.92, p<0.05, Pearson).  The IC50 
for HAL, CPZ and RIS all significantly decreased with incubation time (r =-
1, p<0.05, Spearman; Fig 1E) whereas that for CLZ it did not (r = 0.6, 
p~0.2, Spearman; Fig. 1E). After 72 hrs incubation, CPZ produced the 
most potent inhibition with a pIC50 ~ 5.1 M (8 µM). 
After 24 hrs incubation in APs, intracellular ATP was also decreased in 
relation to the concentration of drug used (Fig. 1F). Comparison of the 
IC50 values for the effect of APs on AB reduction and intracellular ATP 
levels, shows that the latter appears more sensitive, although only CPZ 
and RIS were significantly so (p<0.05, Student’s  t-test). 
Oxygen consumption 
In the absence of glucose, HBVECs respired with a linear rate. This was 
significantly decreased relative to the vehicle control (ANOVA) after 24 hr 
chronic exposure to the APs tested at their IC50 for inhibition of AB 
reduction (Fig. 2A). The greatest decrease on OCR was observed with CPZ 
and HAL and the least with CLZ and RIS (Fig. 2A). Within 2 min of adding 
10 mM glucose the OCR decreased (Crabtree effect), although the relative 
abilities of the APs to decrease OCR was conserved (Fig. 2B).  
 
Mitochondrial complexes 
After 24 hr chronic exposure to the APs, applied at their IC50 for inhibition 
of AB reduction, all four drugs significant decreased the activity of 
complex I and complex III in relation to vehicle (Fig. 2C, D; One sample 
t-test). CPZ was the most efficacious AP at both complex I (p<0.001, 
ANOVA) and complex III (p<0.05, ANOVA).  
Mitochondrial membrane potential 
Flow-cytometry revealed that in vehicle control, HBVECs possessed a 
spread of Δψm values; although the majority of cells had energised values 
of Δψm (predominantly orange), a few were de-energised (lower end of 
orange to green) and a very few had a completely collapsed Δψm (green 
only fluorescence; Fig. 3A). Of the 4 APs incubated for 24 hr at their IC50 
for AB reduction, CPZ had the great impact on mitochondrial membrane 
potential (Fig. 3), causing the greatest proportion of cells with a collapsed 
Δψm, and eradication of cells with partially energised Δψm. The 
percentages of the cell population with exclusively green fluorescence 
(lower right region Fig. 3) CLZ and RIS were insignificantly different to 
vehicle control, unlike CPZ and HAL, for which this was a major 
component of the dye redistribution (Fig. 3B). CPZ, HAL and CLZ, but not 
RIS, were all associated with a significant decrease in the high end of 
orange-green florescence (upper left region Fig. 3). 
 
Discussion. 
The aim of the present study was to investigate to what extent four 
widely used APs had on the mitochondrial function in HBVECs of the BBB. 
Alamar blue and intracellular ATP assay 
For assessment of the steady state redox potential we performed AB 
(resazurin) assays. On cell penetration, resazurin is irreversibly reduced 
to resorufin as the result of different redox enzymes [8]. Like other 
colorimetric assays of redox state, e.g. MTS and MTT, AB output is a 
product of the population average redox potential and cell number. As we 
have previously shown [4], the former effect dominates since that the 
number of viable HBVECs, determined via trypan blue exclusion or lactate 
dehydrogenase leakage, lags in time and also occurs at much higher 
concentrations than the effect of the APs on AB reduction, furthermore 
the decrease in respiration seen in the OCR is for data normalized to cell 
density. The fact that the block of AB reduction was incomplete at the 
highest AP concentrations and incubation times employed indicates cell 
heterogeneity [9], an idea also supported by the range of Δψm values 
observed: data clearly indicative of cellular heterogeneity in the 
mitochondrial energetic status of HBVECs. Furthermore, since CPZ 
completely collapsed Δψm for some cells leaving other cells apparently 
unscathed, is also evidence for bioenergetic heterogeneity in our HBVECs, 
where it appears that. at lest for this particular AP, a tipping point is 
reached that leads to a switch between an energised and deenergized 
mitochondrial state: bistability. 
CPZ was 3-10 x more potent an inhibitor of AB reduction than HAL, RIS 
and CLZ, whom all possessed IC50 values within a 1 log10 unit range. CPZ 
also had the greatest increase in potency with incubation time.  The IC50 
of 22 µM for CPZ in HBVECs after 4 hr incubation is similar to that seen in 
endothelial cells from human umbilical vasculature (25 µM) whereas the 
IC50 value for CPZ in dividing and non-dividing human lymphocytes is far 
higher at 88 µM and >400 µM respectively [10]. Together this data 
suggests that endothelial cells appear to have an increased sensitivity to 
CPZ. The ability of APs to inhibit the redox potential as revealed with the 
AB assay confirm our earlier findings which utilized the MTT assay [4]: 
the inhibition of AB reduction was incomplete at the highest 
concentrations and longest incubations of AP tested.  
The bioenergetic heterogeneity we observe arises from the variability in 
mitochondrial energetic status due to the cells being at different stages of 
the cell cycle [11]: where cells in the S and G2 phases are predominantly 
dependent on glycolytic energy catabolism, and will possess low Δψm 
values, whereas cells in the G1 phase are predominantly aerobic in 
bioenergenesis and will possess high values of Δψm [12]. Consequently, 
there will be cells in G1 phase that are the most vulnerable to 
mitochondrial inhibitors, an idea supported by close inspection of the 
DePsipher data, where, with the exception of RIS,  cells with the highest 
Δψm values (mostly orange fluorescence) are amongst the ones primarily 
lost after incubation with APs. Indeed flow cytometry with propidium 
iodide [4] has revealed that 30-40% of the HBVECs are in S or G2 phase, 
a value similar to the proportion of the cell population shown here to be 
resistant to the actions CPZ as revealed by both the AP and Depsipher 
assays (proportion of cells orange green). 
The decrease in ATP levels observed with APs is the canonical functional 
consequence of the associated decreased redox state. In the neuronal and 
lymphocyte cell lines, SH-SY5Y and U973, Heiser et al. [13] reported 
significantly lower ATP levels after incubation with HAL. In our study, CPZ 
had an IC50 on ATP production lower than HAL, a finding possibly 
explained by the failure of endothelial cells to generate the more potent 
neurotoxic metabolite HPTP (1,2,3,6-tetrahydropyridine) from HAL [14]. 
Effect of antipsychotics on mitochondrial electron transport  
The basal rate of oxygen consumption for HBVECs was ~5.5 nmole O2 107 
cell-1 min-1, a value similar to that seen for other cell lines [5]. Consistent 
with the other bioenergetic assays, CPZ had the greatest potency for the 
inhibition of OCR. CPZ, HAL, RIS and CLZ are well established inhibitors of 
Complex I of the electron transport chain in isolated mitochondrial 
preparations [15, 16, 17), and when tested acutely have estimated IC50 
values of ~35-120 µM for CPZ, ~ 35 µM for HAL, ~65 µM for RIS and 
>200 µM for CLZ. CPZ can also impair, albeit less potently the activities of 
both complex II (IC50 ~ 260 µM [17]) and III (IC50 ~ 150 µM [16]) as 
well as acting as a partial mitochondrial uncoupler (IC50 ~ 50 µM [16]), 
these other effects may synergise to bring about the drastic change 
observed in Δψm with this drug. Indeed, inhibition of Complex I within 
neurons of the cortex by APs has previously been proposed to partly 
explain the extrapyramidal symptoms seen with this class of drugs [18]. 
After 4 hr incubation in intact HBVECs, the IC50 values for the inhibition of 
bioenergenesis as assayed via AB reduction were 22 µM for CPZ, ~92 µM 
for HAL, ~93 µM for RIS and ~61 µM for CLZ, values similar to those 
reported for the inhibition of complex I in isolated mitochondria [15, 16],  
data indicative of Complex 1 as the major target for these drugs in 
HBVECs. This has the consequential effects of reactive oxygen species 
generation, impaired BBB transport function, as well as induction of 
apoptosis, effects we have previously reported for HBVECs in response to 
these APs [4]. Why the IC50 for the inhibition of AB by CPZ in intact cells 
decreased with incubation time and ultimately surpasses its IC50 for its 
direct effect on Complex I in isolated mitochondria is unclear. This is 
unlikely to relate to its behaviour as a blocker of P-GP mediated efflux 
since both HAL and RIS also block P-GP with potencies nearly identical to 
that of CPZ [19].  
Clinical significance 
Of the many drugs that target and impair mitochondrial function [20], 
psychotropic medications are well renowned for this phenomenon. Many 
antipsychotics, in particular CPZ, HAL, RIS and CLZ, have been 
demonstrated to directly damage mitochondria [18, 21]. Indeed, the 
toxicological effects of these drugs on mitochondria are thought to 
underlie some of their central nervous system (CNS) associated 
neurological side effects [4, 22] that are associated with antipsychotic 
overuse and misuse, such as tardive dyskinesia [23], neuroleptic 
associated cerebral oedema [24] and neuroleptic malignant syndrome 
[25]. Indeed the relative potencies of these neuroleptic drugs as inhibitors 
of mitochondrial bioenergetic function is similar to their relative potencies 
as risk factors in the reported incidence of extrapyramidal symptoms, 
including tardive dyskinesia (TD). Our data suggests that an impaired 
bioenergetic function of HBVECs may be involved in the cellular pathology 
underlying TD, whereby antipsychotics energetically compromise HBVECs 
to allow their passage across the BBB and bring about both therapeutic as 
well as adverse neurological actions.  This means that a preclinical in-vitro 
assay of the ability of the newly discovered APs on mitochondrial 
bioenergetics will help to anticipate their efficacy as well as occurrence of 
extrapyramidal manifestations.  
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Figures 
 
Figure 1. Effect of APs on the bioenergetic status of HBVECs from the 
BBB. A-D) Effect of AP concentration on the reduction of AB measured 
after 4, 24, 48 and 72 hrs post drug treatment for the drugs indicated. 
Data are given as percentages of the vehicle controls. Solid lines are 
drawn to the equation given in the methods with IC50 values given in the 
text and panel E). E) IC50 as a function of incubation time for various APs 
as indicated. F) Comparison of IC50 for the decrease in AB reduction and 
cytosolic ATP levels after 24 hr incubation in the APs as indicated. Data 
are shown as means ± S.E.M (n = 6-9).  
 Figure 2. Effect of APs on the oxygen consumption rate (OCR) and 
mitochondrial  complex activity of HMVECs of BBB after 24 hrs pre-
exposure to the APs indicated at their IC50 values for AB reduction. A) 
OCR in the absence of exogenous substrate B) OCR after the addition of 
10 mM glucose. Note the decreased OCR in response to the sugar. Data 
shown as means ± S.E.M (n = 5-6). C & D) Effect of APs on the reduction 
of mitochondrial complexes I (C) and III (D).   Data is expressed as a 
percentage of vehicle control and is shown as means ± S.E.M (n = 9). 
 Figure 3.  Representative quantification of DePsipher stain by flow-
cytometry after incubation with CPZ, HAL, RIS and CLZ for 24 hr at their 
IC50 for AB reduction. The FL3 axis represents cells with orange-green 
fluorescence, while the FL2 axis represents cells with only green 
fluorescence and a collapsed mitochondrial membrane potential. Values 
indicated are the mean values for 3 experiments. The number shown in 
the quadrants are the average values from 3 experiments. B) Effect of 
APs on the proportion of cells expressing green only fluorescence. C) 
Effect of APs on the proportion of cells expressing orange-green.   Data is 
expressed as a percentage of the total cell population and is shown as 
means ± S.E.M (n = 12). 
 
